FMP
Knight Therapeutics Inc.
GUD.TO
TSX
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
6 CAD
-0.1 (-1.67%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
199.52M
243.48M
293.56M
328.2M
371.3M
433.99M
507.27M
592.92M
693.02M
810.03M
-
22.03
20.57
11.8
13.13
16.88
16.88
16.88
16.88
67.56M
42.59M
25.26M
40.9M
64.38M
77.91M
91.06M
106.44M
124.41M
145.42M
33.86
17.49
8.6
12.46
17.34
17.95
17.95
17.95
17.95
35.48M
-5.32M
-37.36M
-9.5M
11.28M
2.62M
3.06M
3.57M
4.18M
4.88M
17.78
-2.19
-12.73
-2.89
3.04
0.6
0.6
0.6
0.6
32.08M
47.91M
62.62M
50.4M
53.11M
75.29M
88.01M
102.87M
120.23M
140.53M
16.08
19.68
21.33
15.36
14.3
17.35
17.35
17.35
17.35
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
411.34M
162.99M
191.22M
154.42M
172.84M
282.69M
330.42M
386.2M
451.41M
527.62M
206.17
66.94
65.14
47.05
46.55
65.14
65.14
65.14
65.14
82.04M
67.41M
94.89M
98.23M
113.53M
140.3M
163.99M
191.68M
224.04M
261.87M
41.12
27.69
32.32
29.93
30.58
32.33
32.33
32.33
32.33
56.51M
72.4M
92.49M
91.83M
102.7M
126.03M
147.31M
172.18M
201.25M
235.23M
28.32
29.73
31.51
27.98
27.66
29.04
29.04
29.04
29.04
44.51M
65.31M
106.06M
85.37M
78.34M
114.9M
134.3M
156.97M
183.47M
214.45M
22.31
26.82
36.13
26.01
21.1
26.47
26.47
26.47
26.47
-20.67M
-224.18M
-25.82M
-9.96M
-31.47M
-106.54M
-124.52M
-145.55M
-170.12M
-198.84M
-10.36
-92.08
-8.79
-3.03
-8.48
-24.55
-24.55
-24.55
-24.55
6
101.13M
18.65
18.65
49.46M
606.8M
656.26M
7.54
92.46
6.43
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
199.52M
243.48M
293.56M
328.2M
371.3M
433.99M
507.27M
592.92M
693.02M
810.03M
67.56M
42.59M
25.26M
40.9M
64.38M
77.91M
91.06M
106.44M
124.41M
145.42M
35.48M
-5.32M
-37.36M
-9.5M
11.28M
2.62M
3.06M
3.57M
4.18M
4.88M
-111.11
-111.11
-111.11
-111.11
-111.11
-111.11
-111.11
-111.11
-111.11
-111.11
35.12M
-12.47M
-25.4M
-7.27M
23.8M
2.32M
2.71M
3.17M
3.71M
4.33M
32.08M
47.91M
62.62M
50.4M
53.11M
75.29M
88.01M
102.87M
120.23M
140.53M
82.04M
67.41M
94.89M
98.23M
113.53M
140.3M
163.99M
191.68M
224.04M
261.87M
56.51M
72.4M
92.49M
91.83M
102.7M
126.03M
147.31M
172.18M
201.25M
235.23M
44.51M
65.31M
106.06M
85.37M
78.34M
114.9M
134.3M
156.97M
183.47M
214.45M
-20.67M
-224.18M
-25.82M
-9.96M
-31.47M
-106.54M
-124.52M
-145.55M
-170.12M
-198.84M
-47.51M
-169.2M
4.58M
9.79M
12.25M
-42.47M
-59.37M
-69.4M
-81.11M
-94.81M
6.43
6.43
6.43
6.43
6.43
-39.9M
-52.41M
-57.56M
-63.22M
-69.43M
-282.49M
6.43
-96.7M
-2.18B
-1.6B
-1.88B
-30.65M
-1.85B
101.13M
-18.28
-18.28 1.328%